<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E0E5E94-3A18-475F-A7A6-B1F5EA270187"><gtr:id>8E0E5E94-3A18-475F-A7A6-B1F5EA270187</gtr:id><gtr:name>International Union Against Tuberculosis and Lung Disease (The Union)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E0E5E94-3A18-475F-A7A6-B1F5EA270187"><gtr:id>8E0E5E94-3A18-475F-A7A6-B1F5EA270187</gtr:id><gtr:name>International Union Against Tuberculosis and Lung Disease (The Union)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2B944851-7705-4F79-819D-F8B04312F6F2"><gtr:id>2B944851-7705-4F79-819D-F8B04312F6F2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Nunn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/221B9401-2B55-43D2-BB9A-8AA7A3B7859B"><gtr:id>221B9401-2B55-43D2-BB9A-8AA7A3B7859B</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Meredith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122888469"><gtr:id>8EEA5C46-411B-40EB-9A52-7631F19F6DBD</gtr:id><gtr:title>Tuberculosis Treatment Trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122888469</gtr:grantReference><gtr:abstractText>Tuberculosis remains a major problem in many countries; numbers of cases reported have increased dramatically since the advent of the HIV-AIDS epidemic. Treatment regimens which are highly effective under controlled trial conditions have been available for many years but need to be given for at least 6 months. Many patients fail to complete treatment since they feel much better after 2-3 months treatment. Shorter and simpler regimens are urgently needed. Giving drugs in combined tablets rather than separately may also improve the chances of a successful outcome.||The CTU is currently conducting two international multi-centre trials and has recently completd a third one which assesses the effectiveness of combined tablets in the first two months of treatment when four drugs are given compared to giving the same drugs separately.||The other two studies are assessing a new drug for tuberculosis, moxifloxacin, to see whether it can enable treatment to be shortened from 6 to 4 months which would have considerable advantages both for the health services in developing countries and the patients. In one of these studies treatment after two months is given intermittently in combination with rifapentine, a long acting derivative of rifampicin, one of the standard anti-tuberculosis drugs.||In addition to the studies in drug sensitive disease the CTU is preparing to start a trial in multi-drug resistant disease using a regiemn which has been developed and implemented with considerable success in Bangladesh.</gtr:abstractText><gtr:technicalSummary>There have been no new anti-tuberculosis drugs for over 40 years; many countries, particularly in sub-Saharan Africa are experiencing increases of 4-5 times the numbers of cases of tuberculosis reported 20 years ago, largely as a consequence of the HIV-AIDS epidemic. Ther is also a growing problem with multi-drug resistant disease (MDR-TB). The CTU is currently involved in conducting two clinical trials of tuberculosis regimens, assessing new drugs. They have recently completed one comparing fixed dose combinations versus separate drugs All of the trials are multi-centre international studies with sites in the developing world.||Study C is an evaluation of a four-drug fixed dose combined tablet for the initial intensive two month phase of treatment for pulmonary TB; if treatment is given in combined tablets it is likely adherence will be better and failures due to drug resistance less likely to occur. Patients receive ethambutol, isoniazid, rifampicin and pyrazinamide, given as either combined tablets or separate tablets. In the continuation phase all patients will receive rifampicin and isoniazid, in a fixed dose tablet, three times a week for 4 months. The primary endpoints are 1) the combined rate of failure at the end of treatment and relapse by 30 months and 2) the occurrence of serious adverse events any time during chemotherapy. Secondary endpoints include sputum culture results at two months (after initiation of chemotherapy).|The REMox and RIFAQUIN trials are assessing the possibility of shortening chemotherapy from 6 to 4 months by substituting moxifloxacin for one of the drugs in the standard regimen. Mouse studies have suggested that substituting moxifloxacin for either ethambutol or isoniazid is likely to enhance the rate of culture conversion. Data from studies in humans have shown there is a correlation between the culture results early in treatment and the likelihood of subsequent relapse. In REMox the two experimental regimens in which moxifloxacin has been substituted are both given for 4 months and compared in a non-inferiority design to the standard 6 month regimen.|RIFAQUIN is also a non-inferiority trial which includes rifapentine as well as moxifloxacin as an experimental drug. Rifapentine is a long acting rifamycin and the two intervention regimens are one in which moxifloxacin are given once weekly in the continuation phase in a standard 6 month duration regimen and one in which the two drugs are given twice weekly in a 4 month duration regimen (2 months intensive phase and 2 months continuation phase). In both REMox and RIFAQUIN the primary endpoint is failure during treatment or subsequent relapse.|A protocol is currently being developed to assess a treatment regimen for MDR-TB; this regimen has been used with considerable success in Bangladesh and needs to be evaluated in other geographical settings.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4138937</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Union Against Tuberculosis and Lung Disease (The Union)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>TREAT-TB</gtr:description><gtr:id>89392DE7-4E9A-40F3-95DE-09BD43457DAA</gtr:id><gtr:impact>No published outcomes yet</gtr:impact><gtr:outcomeId>d6D8q88D8Hj-1</gtr:outcomeId><gtr:partnerContribution>The IUATLD provided openings to enable us to make contact with National TB Programmes with whom we worked to design the Phase III trial.</gtr:partnerContribution><gtr:piContribution>At the request of the IUATLD we have designed and are now conducting a multi-centre randomised trial in MDR-TB</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Union Against Tuberculosis and Lung Disease (The Union)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Study A</gtr:description><gtr:id>2EC61291-FBB1-4F8C-AFCE-AA3E5CE0434F</gtr:id><gtr:impact>Changes to WHO recommendations</gtr:impact><gtr:outcomeId>E9B11F553C1-1</gtr:outcomeId><gtr:partnerContribution>Opportunity to participate in the conduct and analysis of a trial which led to changes in WHO guidelines and to development of subsequent trials.</gtr:partnerContribution><gtr:piContribution>We were responsible for the data analysis and part of the writing process</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Discussions regarding surrogacy of early endpoints in TB trials</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67066CF4-86E9-4FED-9A68-538C4F1B1426</gtr:id><gtr:impact>Discussions were held with the FDA and were relevant to future requirements for early licensing of new drugs or drug regimens

FDA noted application of the results presented to future policy</gtr:impact><gtr:outcomeId>5460ba1c4dc649.33572081</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to EMA of surrogacy data from phase III clinical trials relevant to future licensing policy</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>31A2DC81-FD08-4324-829E-6DE101912F02</gtr:id><gtr:impact>EMA were very interested in findings presented which would inform future policy for licensing of new TB drugs

Expectation of further contact with EMA to discuss guidance on licensing policy</gtr:impact><gtr:outcomeId>5460bb37a28419.78153798</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1057040</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP, REMoxTB &amp;amp; RIFAQUIN trials</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>0BDBA994-5B53-423A-973C-36A2FA853285</gtr:id><gtr:outcomeId>A0DF19CD7DF0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1241416</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TB Alliance, REMox TB Trial</gtr:description><gtr:fundingOrg>The Global Alliance for TB Drug Development</gtr:fundingOrg><gtr:id>6E8A6C8D-DE9B-4142-9CA8-FFD079F0EF9B</gtr:id><gtr:outcomeId>31B26E92B3D0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>577292</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>USAID funding for MDR_TB trial/USAID</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>United States Agency for International Development</gtr:fundingOrg><gtr:id>6E8DE7CC-518A-48D2-80E3-0798A69D5D58</gtr:id><gtr:outcomeId>eoGbA4eeXvE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1158863</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Global Health Group</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J012513/1</gtr:fundingRef><gtr:id>F9DA26E8-F803-48DF-9B1E-4571C390C2FA</gtr:id><gtr:outcomeId>SSzYorpbxiR</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Key reference in guideline</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for cotrimoxazole prophylaxis in HIV-related infections</gtr:guidelineTitle><gtr:id>8E14059C-9A1F-4DB1-BA28-D541B3045D88</gtr:id><gtr:impact>This was the largest trial demonstrating the benefits of cotrimoxazole prophylaxis in patients dually infected with TB and HIV</gtr:impact><gtr:outcomeId>K7XWrBz7Y8U</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.who.int/hiv/pub/guidelines/ctx/en/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Key trial in revision of TB treatment guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>WHO TB treatment guidelines</gtr:guidelineTitle><gtr:id>C565EFD2-846B-4B82-BEB1-6727A73C5B37</gtr:id><gtr:impact>As a result of Study A treatment guidelines worldwide were changed to stop further use of a regimen which had previoulsy been recommended by WHO. Instead WHO recommended that all patients should receive 6 months of isoniazid and rifampicin.</gtr:impact><gtr:outcomeId>JpEj1YSbHfE</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.who.int/tb/publications/2010/9789241547833/en/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>As a result of conducting a number of non-inferiority trials in TB appropriate analysis techniques are indevelopment and one publication already refers to these.</gtr:description><gtr:id>6628EA77-6FBC-4AED-95BB-09D881DBF583</gtr:id><gtr:impact>Shared experiences with others conducting similar trials using this design.</gtr:impact><gtr:outcomeId>25C8F975EB3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Methology for analysing non-inferiority trials in TB</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6C16A963-179A-4CD3-A921-1DD2FB6B8551</gtr:id><gtr:title>Innovative trial designs are practical solutions for improving the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14424_24_22448027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>714F4FB6-6205-49A3-949C-FFD60D962EA1</gtr:id><gtr:title>Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0e198d5c1abcb1e04f1d458f47bb474"><gtr:id>a0e198d5c1abcb1e04f1d458f47bb474</gtr:id><gtr:otherNames>Heinrich N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56bc699ad25848.17193375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C39D837-E549-40F2-8A3C-9E8F46398FEC</gtr:id><gtr:title>The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations</gtr:title><gtr:parentPublicationTitle>Journal of Antimicrobial Chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/865b4c1cfe713c9197ab4079f9a2f66e"><gtr:id>865b4c1cfe713c9197ab4079f9a2f66e</gtr:id><gtr:otherNames>Bowness R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56bc657510c901.95563533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E554802-A5C6-407A-9D54-8666C17E6068</gtr:id><gtr:title>Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda47a46d598194ab5b2087f641a0972"><gtr:id>cda47a46d598194ab5b2087f641a0972</gtr:id><gtr:otherNames>Lienhardt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>gacL1Bknwkr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EF98EB3-BB0F-41F7-A06F-AE5233F0A9A7</gtr:id><gtr:title>What is the role of clinical trials for the treatment of tuberculosis and what are the alternatives?</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f618fdecf7990e35858764386f35ae"><gtr:id>e8f618fdecf7990e35858764386f35ae</gtr:id><gtr:otherNames>Nunn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>FemgoB9eEvq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC207EC-211F-4816-8E92-FBE634F8BA94</gtr:id><gtr:title>An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14424_24_23667677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F066B73-E3DF-4F0D-8DE9-92BA36BBD186</gtr:id><gtr:title>The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>56bc699bd42ce6.73709133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C5CF4CF-BEE6-4FF6-9762-12C0FAAE9103</gtr:id><gtr:title>High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a72feaecceaffabb86a703b98dc98e6"><gtr:id>5a72feaecceaffabb86a703b98dc98e6</gtr:id><gtr:otherNames>Jindani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5460b6096b9b20.96613783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0E5836C-5CF8-4BB5-889C-47C537DD5731</gtr:id><gtr:title>Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>FBAC733C82B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FFF4B30-163C-4832-A894-CD16CABD4AF5</gtr:id><gtr:title>A Step toward an Optimized Rifampin Dose Completed.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cefe586c27567da317380b1fa0b162"><gtr:id>e7cefe586c27567da317380b1fa0b162</gtr:id><gtr:otherNames>Boeree MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56bc699c152cb6.96708063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>016355CC-2490-4DF7-95F2-E1AFB1C3DF10</gtr:id><gtr:title>Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5460b7343341e3.00288688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E5E04AF-A3FD-4C0B-BD4D-0082D644554B</gtr:id><gtr:title>A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cefe586c27567da317380b1fa0b162"><gtr:id>e7cefe586c27567da317380b1fa0b162</gtr:id><gtr:otherNames>Boeree MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56bc699b9d33b6.76855296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F617908F-7EF1-4A6E-B80C-E2136A5E6064</gtr:id><gtr:title>Advancing the development of tuberculosis therapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36452f22be0a13b403ebc6cd4d8ba2d3"><gtr:id>36452f22be0a13b403ebc6cd4d8ba2d3</gtr:id><gtr:otherNames>Zumla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_14424_24_22378254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D116A4C-57A4-4DE7-B837-34BA28246861</gtr:id><gtr:title>Timing of relapse in short-course chemotherapy trials for tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>REvqKHtbd6Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056111A5-3A30-42DB-9EBC-B69FA4C3E850</gtr:id><gtr:title>Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5460d366b20002.85485416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87C357CF-67CE-48C9-B64F-2B3424A4687C</gtr:id><gtr:title>Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723acb618989628fb0e91debea580ad8"><gtr:id>723acb618989628fb0e91debea580ad8</gtr:id><gtr:otherNames>Perrin FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>DG6uNu6kdHe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B7A1983-B076-4619-9066-111309ABA048</gtr:id><gtr:title>Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b02e14a0c27e80d4775305c52654a4"><gtr:id>41b02e14a0c27e80d4775305c52654a4</gtr:id><gtr:otherNames>Gillespie SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5460b5e078adf0.38944932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1062EF87-343F-4556-B804-A72C1495A7E9</gtr:id><gtr:title>Population differences in death rates in HIV-positive patients with tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61d92e7da9bd221f7739803aa701789"><gtr:id>f61d92e7da9bd221f7739803aa701789</gtr:id><gtr:otherNames>Ciglenecki I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>09E24A630D5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D001847-4099-4516-9CD5-E507129BB2B8</gtr:id><gtr:title>Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>LMmqwNCoAXN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36507F1C-FE1F-4258-BA82-2A6C288E1B6C</gtr:id><gtr:title>Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>SZq3FhSPcL7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>285F0EE8-473C-44BD-884E-2CF65847446D</gtr:id><gtr:title>Global tuberculosis drug development pipeline: the need and the reality.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51bf4dfa986916ecad0537b64e1e1c57"><gtr:id>51bf4dfa986916ecad0537b64e1e1c57</gtr:id><gtr:otherNames>Ma Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>MashpgDQ4Ex</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5200B504-3E60-4D0B-9206-699BBBB4FF28</gtr:id><gtr:title>Treatment of pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>Current opinion in pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f618fdecf7990e35858764386f35ae"><gtr:id>e8f618fdecf7990e35858764386f35ae</gtr:id><gtr:otherNames>Nunn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1070-5287</gtr:issn><gtr:outcomeId>pm_14424_24_23528955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60FFAC39-4983-4189-970C-B9FD8F422ED3</gtr:id><gtr:title>Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>25772EE2076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1F0C9B1-4EA0-420D-B03B-D7CDC93EE516</gtr:id><gtr:title>Alternative approaches to tuberculosis treatment evaluation: the role of pragmatic trials.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>Kv9dWsWm7ZZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4FA5FF1-ADFC-421C-AAC1-D8CB1C3CE03B</gtr:id><gtr:title>New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/021ff33bb22a80766a10b437490d5710"><gtr:id>021ff33bb22a80766a10b437490d5710</gtr:id><gtr:otherNames>Zumla AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5460ddd3e99186.03186999</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122888469</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>